Atlas Trials

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Clinical trial NCT05320393 · COMPLETED

Trial details

NCT number
NCT05320393
Sponsor
Evolus, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Glabellar Frown Lines
Start date
2022-03-30
Primary completion
2023-05-22
Enrollment
154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.